Department of Medical Pharmacology & Physiology, University of Missouri, Columbia, MO 65212, USA.
Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Function (Oxf). 2024 Sep 10;5(5). doi: 10.1093/function/zqae033.
Lymphatic dysfunction is an underlying component of multiple metabolic diseases, including diabetes, obesity, and metabolic syndrome. We investigated the roles of KATP channels in lymphatic contractile dysfunction in response to acute metabolic stress induced by inhibition of the mitochondrial electron transport chain. Ex vivo popliteal lymphatic vessels from mice were exposed to the electron transport chain inhibitors antimycin A and rotenone, or the oxidative phosphorylation inhibitor/protonophore, CCCP. Each inhibitor led to a significant reduction in the frequency of spontaneous lymphatic contractions and calculated pump flow, without a significant change in contraction amplitude. Contraction frequency was restored by the KATP channel inhibitor, glibenclamide. Lymphatic vessels from mice with global Kir6.1 deficiency or expressing a smooth muscle-specific dominant negative Kir6.1 channel were resistant to inhibition. Antimycin A inhibited the spontaneous action potentials generated in lymphatic muscle and this effect was reversed by glibenclamide, confirming the role of KATP channels. Antimycin A, but not rotenone or CCCP, increased dihydrorhodamine fluorescence in lymphatic muscle, indicating ROS production. Pretreatment with tiron or catalase prevented the effect of antimycin A on wild-type lymphatic vessels, consistent with its action being mediated by ROS. Our results support the conclusion that KATP channels in lymphatic muscle can be directly activated by reduced mitochondrial ATP production or ROS generation, consequent to acute metabolic stress, leading to contractile dysfunction through inhibition of the ionic pacemaker controlling spontaneous lymphatic contractions. We propose that a similar activation of KATP channels contributes to lymphatic dysfunction in metabolic disease.
淋巴功能障碍是多种代谢疾病的潜在组成部分,包括糖尿病、肥胖症和代谢综合征。我们研究了 KATP 通道在急性代谢应激下对淋巴收缩功能障碍的作用,这种应激是由抑制线粒体电子传递链引起的。从小鼠的隐窝淋巴管中分离出离体的淋巴管,暴露于电子传递链抑制剂安密霉素 A 和鱼藤酮,或氧化磷酸化抑制剂/质子载体 CCCP。每种抑制剂都导致自发性淋巴收缩的频率和计算出的泵流量显著降低,而收缩幅度没有显著变化。收缩频率可被 KATP 通道抑制剂格列本脲恢复。Kir6.1 全身性缺陷的小鼠或表达平滑肌特异性显性负性 Kir6.1 通道的小鼠的淋巴管对抑制作用具有抗性。安密霉素 A 抑制了淋巴肌中自发产生的动作电位,而格列本脲逆转了这种作用,证实了 KATP 通道的作用。安密霉素 A,但不是鱼藤酮或 CCCP,增加了淋巴肌中二氢罗丹明荧光,表明 ROS 的产生。预先用 tiron 或 catalase 预处理可防止安密霉素 A 对野生型淋巴管的作用,这与它通过 ROS 介导的作用一致。我们的结果支持这样的结论,即淋巴肌中的 KATP 通道可以通过减少线粒体 ATP 产生或 ROS 生成而被直接激活,这是由急性代谢应激引起的,通过抑制控制自发性淋巴收缩的离子起搏器导致收缩功能障碍。我们提出,类似的 KATP 通道激活可能导致代谢疾病中的淋巴功能障碍。